Parabilis Medicines (#PBLS) is a clinical-stage biotech developing its Helicon™ peptide platform to target historically difficult-to-drug proteins. Its lead program, zolucatetide (FOG-001), targets the β-catenin/TCF interaction and is being studied across desmoid tumors, familial adenomatous polyposis and other solid tumors. 💰 Strong Institutional Backing: Parabilis raised $305M in a Series F financing co-led by RA Capital, FMR and Janus Henderson, with participation from Cormorant, GV, ARCH Venture Partners, venBio and other investors. 🏦 RA Capital remains a major holder: SEC filings show RA Capital and affiliated funds holding ~28.9M shares, representing a significant ownership position. 💎 Baker Bros. also holds PBLS: Q2 2026 13F data shows 500,000 shares held by Baker Bros. Advisors. 🧬 Clinical Catalyst: Parabilis reported preliminary clinical evidence showing reductions in duodenal polyposis and a co-existing desmoid tumor in a patient with FAP in its ongoing Phase 1/2 trial. The company plans further development of zolucatetide, including a planned Phase 3 desmoid-tumor program. 🚀 Bottom Line: #PBLS is worth watching because it combines a novel peptide platform, meaningful biotech-specialist institutional backing, substantial financing and multiple clinical development opportunities. However, it remains a clinical-stage biotech with no approved product, so clinical results and execution remain the key risks. 💎 Want to track institutional moves like PBLS? Explore ThinkSabio’s TS Platinum & Diamond Reports and research institutional positioning with a 7-day FREE trial. Start Your 7-Day FREE ThinkSabio Trial